Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on
standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2
expression, patients can participate in the trial after obtaining informed consent.
Patients will be treated with weekly paclitaxel-trastuzumab.